Firms

Qiming Venture Partners

Qiming Venture Partners

Shanghai, China · Beijing, China · Hong Kong · Suzhou, China · Singapore

qimingvc.com

Qiming Venture Partners is a China-focused venture investment platform founded in 2006, investing at early and growth stages in technology and healthcare. Its current published team includes 40 named investment and operating professionals, led by founding managing partners Duane Kuang and Gary Rieschel and managing partners William Hu and Alex Zhou. Investments span AI models and infrastructure, semiconductors, robotics, autonomous systems, biotechnology, diagnostics, medical devices and healthcare services. Relevant portfolio companies include Alamar Biosciences, Insilico Medicine, TandemAI, SceneRay and GenLight. Current contacts list offices in Shanghai, Beijing, Hong Kong, Suzhou and Singapore. The February2024 website terms identify Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd. and affiliates as Qiming; the copyright footer names the Beijing affiliate. USD fund GP and legal vehicle identities are separately documented in issuer filings. This profile represents the China platform, preserving the distinct existing Qiming Venture Partners USA profile and its financial references. The USD Fund VIII announcement reported USD2.5 billion collectively for the main and parallel healthcare funds, not USD2.5 billion for each. RMB Fund VII first closed at RMB4.7 billion in July2022 and finally at RMB6.5 billion in May2023; the first close is included in the final total. USD Fund VII first closed at USD1.1 billion in April2020 and finally at USD1.2 billion in November2020. Historical partner Nisa Leung departed in February2025 and is not included in the current roster. Firm-level aggregate capital, investment targets and proposed Fund IX offerings are not recorded as separate cash raises. The March31,2026 SEC exempt-reporting filings identify Qiming Cayman, Ltd. (CRD160844) as the Qiming Venture Partners adviser for older USD fund vehicles and Qiming Global Management, LLC (CRD309395) as adviser for USD VII, VIII, VIII-HC and IX-A/B/C vehicles. Both list Hong Kong principal offices. They are related China-platform legal advisers, with separate vehicles and GPs; no SEC registered-adviser status is claimed. Form ADV asset values are portfolio gross assets rather than capital newly raised. Current Fund IX legal vehicles are documented without a verified final-close amount.

Founded
2006
Type
Venture capital

Funds9

  • Qiming Venture RMB Fund VIICN¥6.5B

    Own May18,2023 final close RMB6.5B, including the July11,2022 RMB4.7B first close. USD700M equivalent of that first close is not additional new cash.

  • Qiming Venture USD Fund VIII (main and parallel healthcare family)$2.5B

    Own July11,2022 actual USD2.5B pooled close explicitly includes the main FundVIII and parallel FundVIII-HC healthcare fund. Separate component allocations are undisclosed, so2.5B is recorded once for the family rather than twice across legalvehicles.

  • Qiming Venture RMB Fund VICN¥2.85B

    Own January26,2021 final close RMB2.852B; includes November2020 first close. Approximate2.9B summaries and firm5.9BAUM are not separate fundraising.

  • Qiming Venture USD Fund VII$1.2B

    Own November18,2020 final close USD1.2B. Includes the earlier April9,2020 USD1.1B first close; those are successive closings of one fund, not2.3B total.

  • Qiming Venture RMB Fund VCN¥2.1B

    Actual RMB2.1B close announced April16,2018 in issuer-distributed body, website repost April18. USD-equivalent aggregate1.39B is not an extra fund or cash event.

  • Qiming Venture USD Fund VI$935M

    Issuer-distributed announcement body is dated April16,2018; website publication heading is April18. Actual USD935M closed commitments, separate from RMB Fund V and US Healthcare Fund I. US fund is not recorded again under the China manager.

  • Qiming Venture USD Fund IV$500M

    Manager own April10,2014 announcement confirms successful USD500M close. Announcement day is not an assumed subscription settlement day.

  • Qiming Venture USD Fund III$450M

    Own issuer release body May19,2011 confirms actual USD450M third fund close; website repost heading May23. Announcement body date retained; no assumed settlement day.

Team

Operations and support

Alex ZhouAlex ZhouManaging Partner
Alexander Sinclair-WilsonAlexander Sinclair-WilsonPrincipal
Bin LiuBin LiuVice President
Bonnie WangBonnie WangPartner
Cecilia YinCecilia YinVice President
Cindy LiuCindy LiuPrincipal
David ChuDavid ChuPartner
Dingzheng LiDingzheng LiVice President
Duane KuangDuane KuangFounding Managing Partner
Frost LamFrost LamAssociate
Gary RieschelGary RieschelFounding Managing Partner
Grace LeeGrace LeePartner & Group COO
Janet YuJanet YuPartner & Head of RMB Funds
Jinda GaoJinda GaoPrincipal
Jing LiuJing LiuPrincipal
Joyce ChengJoyce ChengAssociate
Kan ChenKan ChenPartner
Kuantai YehKuantai YehPartner
Lianbo LiLianbo LiVice President
Motao SunMotao SunVice President
Nan ChenNan ChenPrincipal
Oscar ZhangOscar ZhangPartner
Pu ShiPu ShiVice President
Qi HuQi HuPrincipal
Remus WongRemus WongVice President
Shaohua LiuShaohua LiuAssociate
Shidong XiShidong XiVice President
Shiyu WangShiyu WangPartner
Shuo HuangShuo HuangVice President
Shuo MaoShuo MaoPrincipal
Tianqi LengTianqi LengVice President
Weibin HuWeibin HuVice President
William HuWilliam HuManaging Partner
Xiaofei ZhouXiaofei ZhouVice President
Xin ZhaoXin ZhaoVice President
Xueyao ChenXueyao ChenVice President
Yi ZhangYi ZhangPartner, China COO and General Counsel
Yuanhao WangYuanhao WangVice President
Yuxin FuYuxin FuVice President
Zhiyuan ZhouZhiyuan ZhouVice President

Co-investing

Investments